CereScan Corp. Selected to Join Cavendish Global and Present at Health Impact Forums

Littleton, CO November 25, 2014

CereScan, a national leader in functional brain diagnostics and molecular imaging, was selected as an Innovation Partner and invited to present at the Cavendish Global Health Impact Forums that took place November 10-13th at Oxford University in the UK and will take place April 27-30, 2015 in San Diego. The Health Impact Forums help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within the health and life sciences. To accomplish this mission, the Forums showcase presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. Michael Moffat, Cavendish co-founder and President explains, “With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. CereScan’s advanced technologies and pioneering research clearly qualified them as an Innovation Partner and we are delighted that they have joined the Cavendish family.”

“We are honored to be selected as an Innovation Partner and to present our leading-edge research at these unique events. It is further recognition of our innovative approaches in the brain health arena,” said Dr. Richard Fort, CereScan President & COO. “We welcome the opportunity to interact with many of the world’s leading scientific minds, thought-leaders and philanthropic families who are dedicated to the common cause of improving the health and lives of people around the world.”

At the November Health Impact Forum, CereScan presented preliminary results of a research program, the Invisible Brain Injury Project, aimed at assessing a novel treatment for traumatic brain injuries (TBIs). This research program, funded by the Tug McGraw Foundation, recruited veterans who served in the Middle East conflicts and suffered TBIs. The aim of this project is to identify effective treatments of TBI and accelerate their adoption in brain healthcare. Final results of the IBIP will be presented at the next Cavendish Health Impact Forum in April, 2015 in San Diego.

About CereScan
CereScan combines state-of-the-art SPECT and PET/CT brain imaging technology with a patient-centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative, functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the biological basis of their conditions. In a variety of legal settings, CereScan provides objective evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For brain therapy researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit www.CereScan.com.

About Cavendish Global
Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forums provide family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world. For more information, please visit http://cavendishglobal.com.

CereScan Earns ACR Nuclear Medicine Accreditation

CereScan has been awarded a three-year term of accreditation in nuclear medicine as the result of a recent review by the American College of Radiology (ACR). Nuclear medicine is a branch of medical imaging that uses safe amounts of radioactive material, to diagnose and treat a variety of diseases, including many types of cancers, heart disease, and certain other abnormalities within the body and brain.

The ACR gold seal of accreditation represents the highest level of image quality and patient safety. It is awarded only to facilities satisfying the ACR Practice Guidelines and Technical Standards after a peer-review evaluation by independent, board-certified physicians and medical physicists who are experts in the field. Image quality, personnel qualifications, adequacy of facility equipment, quality control procedures, and quality assurance programs are all assessed. The findings are reported to the ACR Committee on Accreditation, which subsequently provides the practice with a comprehensive report they can use for continuous practice improvement.

“ACR accreditation confirms the quality and validity of our Nuclear Medicine SPECT imaging procedures and will give our research partners and patients added confidence regarding our evaluations,” said Dr. Richard Fort, President & COO of CereScan.

The ACR is a national professional organization serving more than 36,000 diagnostic/interventional radiologists, radiation oncologists, nuclear medicine physicians, and medical physicists with programs focusing on the practice of medical imaging and radiation oncology and the delivery of comprehensive health care services.

CereScan is the nation’s leader in providing statistically measured brain diagnostics based on a new generation of imaging software and SPECT (Single Photon Emission Computed Tomography) neuroimaging technologies. Since 2009, patients from all over the country and throughout the world have consulted Denver-based CereScan and its leading physicians concerning chronic neurological and psychiatric issues.

Referring and treating medical experts can rely on CereScan to offer differentiated diagnoses on a wide array of brain-based disorders including:

  • Traumatic Brain Injury
  • Toxic Brain Injury
  • Alzheimer’s Disease
  • Mild Cognitive Impairment
  • Other Dementias
  • Depression
  • Parkinsonian Syndrome
  • Obsessive Compulsive Disorder
  • Bipolar Disorder
  • ADD/ADHD
  • Anxiety Disorder

About CereScan
CereScan combines state-of-the-art SPECT and PET/CT brain imaging technology with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the biological basis of their conditions. In a variety of legal settings, CereScan provides objective evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit http://www.CereScan.com.

CereScan Extending Reach with Medical Imaging Center in Louisiana

CereScan Corp. is proud to announce a groundbreaking neuroimaging partnership agreement with Diagnostic Imaging Services (DIS) in Metairie, Louisiana. This collaborative effort will expand CereScan’s sophisticated brain diagnostic products and DIS’s state of the art neuroimaging capabilities to adults and children who are suffering from “invisible brain issues.” This partnership creates a powerful combination of cutting edge technologies focused on identifying specific brain related problems in areas such as traumatic brain injury, Alzheimer’s disease, and attention deficit disorder. The State of Louisiana and the southeast region of the country now have easy access to the capabilities that these two companies can deliver to medical professionals who are focused on finding solutions for patients with chronic brain disorders.

CereScan is the nation’s leader in providing statistically measured brain diagnostics based on a new generation of imaging software and SPECT (Single Photon Emission Computed Tomography) neuroimaging technologies. Since 2009, patients from all over the country and throughout the world have consulted Denver-based CereScan and its leading physicians concerning chronic neurological and psychiatric issues. By partnering with DIS and their extensive experience in nuclear imaging, this Metairie-center will now offer unmatched functional brain imaging capabilities in the southeast.

Referring and treating medical experts can now rely on CereScan and DIS to offer differentiated diagnoses on a wide array of brain-based disorders including:

  • ADD/ADHD
  • Alzheimer’s Disease
  • Anxiety Disorder
  • Bipolar Disorder
  • Dementia
  • Depression
  • OCD
  • Parkinson’s Disease
  • Traumatic Brain Injury
  • Toxic Brain Injury
  • Learning Disorders

“We are excited about the opportunity to team up with Diagnostic Imaging Services in order to serve patients and medical professionals in Louisiana and other nearby states. This business relationship will enable us to further expand our high-quality diagnostic brain imaging capabilities to those patients who are seeking hope and solutions to their mental health problems.” said John Kelley, CEO, at CereScan.

With experienced, friendly and professional staffs and facilities designed specifically for comfort and care, CereScan and DIS are dedicated to excellence in patient care. This market expansion provides patients from all over the country will new options in accessing diagnostic technologies that were not in existence a few years ago.

“DIS has always strived to be innovative, offering exams that take advantage of advanced diagnostic techniques and technology,” said Michael Holmes, Chief Executive Officer of DIS. “Partnering with CereScan is the type of continuing synergy we look for that best serves the local community and beyond in the area of medical imaging,” he added.

About CereScan
CereScan combines state-of-the-art SPECT and PET brain imaging technology with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. For clinical patients, CereScan helps them and their physicians better understand the biological basis of their conditions. For forensic cases, CereScan provides objective evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit www.CereScan.com.

About Diagnostic Imaging Services
DIS is the largest independently-owned outpatient imaging provider in Louisiana. Since 1973, this New Orleans-area organization has offered screening and diagnostic exams in areas such as mammography, magnetic resonance imaging (MRI), computed tomography (CT), PET/CT and nuclear medicine, with locations in Metairie, New Orleans, Marrero, Covington and Slidell, Louisiana.

CereScan Partners with The Denver Post to Shed Light on Child Trauma and SPECT Brain Imaging

The Denver Post published an article as a part of an eight part investigative series this weekend about how children who are neglected or abused during adolescence are more likely to have brain and body abnormalities in adulthood. The article explains that “Children who are beaten, starved or abandoned are likely to suffer emotional trauma so severe that it can impair the way their bodies and brains grow up — and, if never addressed, cause lifelong health problems.” The article then goes on to discuss some of the newest research in treating neglected and abused children. Dr. Bruce Perry, a researcher at ChildTrauma Academy in Houston, Texas, explains that many of these children are misdiagnosed with a mental disorder when in reality the problem is a “manifestation of trauma.” With the help of Single-Photon Emission Computed Tomography (SPECT) brain imaging, doctors can determine if these children are suffering from a mental disorder or a brain abnormality due to the trauma sustained. As a result of the scan, doctors were able to put these children on a more precise treatment regimen that had them in care for a shorter amount of time. The article also tells the story of Grant Oakes, a man who became the legal guardian of his grandson after the child’s mother, a drug user, was abused by her partner in front of him. As he reached his teens, “the child began using marijuana, skipping school and eventually threatening suicide.” With the help of SPECT brain imaging at CereScan, Oakes’ grandson was diagnosed with Bipolar Disorder and is now on a mood-stabilizing medication. The family says they have seen improvements in his behavior. SPECT scans can help answer questions that families and caregivers of children who have been abused. While these scans can be pricey, they may ultimately save money, for both caregivers and the government, by diagnosing the problem earlier and avoiding therapy on a trial and error basis. “I love this kid, but we went through hell and back,” Oakes said. “If we would do these scans and get people help much earlier, then there would be so much money saved in the court system and in doctor visits, not to mention avoiding the grief that people go through.”

The Denver Post article can be found here.